Antiretroviral therapy-induced liver alterations

Current Opinion in HIV and AIDS

Volumn 2, Issue 4, 2007, Pages 293-298

  Walker, Ulrich A ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Antiretroviral therapy; Hepatitis C virus; HIV; Liver; Mitochondria; Steatosis

Indexed keywords

ANTIRETROVIRUS AGENT; APLAVIROC; ATAZANAVIR; ATAZANAVIR PLUS RITONAVIR; ATAZANAVIR PLUS SAQUINAVIR; DIDANOSINE; EFAVIRENZ; ENFURVITIDE; INDINAVIR; LOPINAVIR PLUS RITONAVIR; MARAVIROC; NEVIRAPINE; RITONAVIR; STAVUDINE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TIPRANAVIR; UNCLASSIFIED DRUG; URIDINE; VICRIVIROC; ZALCITABINE; ZIDOVUDINE;

ADVERSE OUTCOME; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINOTRANSFERASE BLOOD LEVEL; CHILL; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FATTY LIVER; FEVER; GILBERT DISEASE; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPOTENSION; JAUNDICE; LACTIC ACIDOSIS; LIVER FAILURE; LIVER FIBROSIS; LIVER TOXICITY; NAUSEA; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; RASH; REVIEW; RIGOR; SIDE EFFECT; TREATMENT OUTCOME; VIRUS TRANSMISSION; VOMITING;

EID: 34250684073     PISSN: 1746630X     EISSN: 17466318     Source Type: Journal    
DOI: 10.1097/COH.0b013e328122dbaa     Document Type: Review

References (60)

1. Nunez MJ, Martin-Carbonero L, Moreno V, et al. Impact of antiretroviral treatment-related toxicities on hospital admissions in HIV-infected patients. AIDS Res Hum Retroviruses 2006; 22:825-829. This systematic analysis of hospital admissions attributes a major role to hepatotoxicity.
2. Shah I. Adverse effects of antiretroviral therapy in HIV-1 infected children. J Trop Pediatr 2006; 52:244-248.
3. Sharma P, Balan V, Hernandez J, et al. Hepatic steatosis in hepatitis C virus genotype 3 infection: does it correlate with body mass index, fibrosis, and HCV risk factors? Dig Dis Sci 2004; 49:25-29.
4. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006; 44:1648-1655.
5. Monto A, Dove LM, Bostrom A, et al. Hepatic steatosis in HIV/hepatitis C coinfection: prevalence and significance compared with hepatitis C monoinfection. Hepatology 2005; 42:310-316.
6. Sulkowski MS, Mehta SH, Torbenson M, et al. Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus. AIDS 2005; 19:585-592.
7. McGovern BH, Ditelberg JS, Taylor LE, et al. Hepatic steatosis is associated with fibrosis, nucleoside analogue use, and hepatitis C virus genotype 3 infection in HIV-seropositive patients. Clin Infect Dis 2006; 43:365-372. In this cohort of 260 HIV/HCV-coinfected patients, steatosis was prevalent and associated with the severity of liver fibrosis. Didanosine, stavudine and HCV genotype 3 were associated with hepatic steatosis.
8. Gaslightwala I, Bini EJ. Impact of human immunodeficiency virus infection on the prevalence and severity of steatosis in patients with chronic hepatitis C virus infection. J Hepatol 2006; 44:1026-1032.
9. Van Huyen JP, Batisse D, Heudes D, et al. Alteration of cytochrome oxidase subunit I labeling is associated with severe mitochondriopathy in NRTI-related hepatotoxicity in HIV patients. Mod Pathol 2006; 19:1277-1288.
10. Lemoine M, Barbu V, Girard PM, et al. Altered hepatic expression of SREBP-1 and PPARgamma is associated with liver injury in insulin-resistant lipodystrophic HIV-infected patients. AIDS 2006; 20:387-395.
11. Riddle TM, Kuhel DG, Woollett LA, et al. HIV protease inhibitor induces fatty acid and sterol biosynthesis in liver and adipose tissues due to the accumulation of activated sterol regulatory element-binding proteins in the nucleus. J Biol Chem 2001; 276:37514-37519.
12. Zhou H, Gurley EC, Jarujaron S, et al. HIV protease inhibitors activate the unfolded protein response and disrupt lipid metabolism in primary hepatocytes. Am J Physiol Gastrointest Liver Physiol 2006; 291: G1071-G1080.
13. Aranzabal L, Casado JL, Moya J, et al. Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 2005; 40:588-593.
14. Verma S, Wang CH, Govindarajan S, et al. Do type and duration of antiretroviral therapy attenuate liver fibrosis in HIV-hepatitis C virus-coinfected patients? Clin Infect Dis 2006; 42:262-270. In 381 patients, HIV-HCV-coinfected patients effectively treated with antivirals had liver fibrosis comparable with HCV monoinfection. Increased scores were found with ineffective ART.
15. Verma S. HAART attenuates liver fibrosis in patients with HIV/HCV co-infection: fact or fiction? J Antimicrob Chemother 2006; 58:496-501.
16. Bräu N, Salvatore M, Rios-Bedoya CF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44:47-55. This study shows that HIV/HCV-coinfected patients with effective ART have a slower progression of liver fibrosis than those with high HIV viral loads and a fibrosis progression rate similar to HCV-monoinfected individuals.
17. Mehta SH, Thomas DL, Torbenson M, et al. The effect of antiretroviral therapy on liver disease among adults with HIV and hepatitis C coinfection. Hepatology 2005; 41:123-131.
18. Kramer JR, Giordano TP, Souchek J, et al. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am J Gastroenterol 2005; 100:56-63.
19. Kramer JR, Giordano TP, Souchek J, El Serag HB. Hepatitis C coinfection increases the risk of fulminant hepatic failure in patients with HIV in the HAART era. J Hepatol 2005; 42:309-314.
20. Servoss JC, Kitch DW, Andersen JW, et al. Predictors of antiretroviral-related hepatotoxicity in the adult AIDS Clinical Trial Group (1989-1999). J Acquir Immune Defic Syndr 2006; 43:320-323. An analysis of hepatotoxicity among a cohort of 8851 patients.
21. Sanne I, Mommeja-Marin H, Hinkle J, et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. J Infect Dis 2005; 191:825-829.
22. Dieterich DT, Robinson PA, Love J, Stern JO. Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004; 38 (Suppl 2):S80-S89.
23. Marazzi MC, Germano P, Liotta G, et al. Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical transmission in an African cohort of HIV-1-infected pregnant women. HIV Med 2006; 7:338-344. The incidence of grade 3-4 hepatotoxicity was relatively low in this study, with a high dropout rate.
24. Lyons F, Hopkins S, Kelleher B, et al. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy. HIV Med 2006; 7:255-260. In a cohort of 123 women, eight women had significant hepatotoxicity, two women died.
25. Joy S, Poi M, Hughes L, et al. Third-trimester maternal toxicity with nevirapine use in pregnancy. Obstet Gynecol 2005; 106:1032-1038.
26. Martin AM, Nolan D, James I, et al. Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts. AIDS 2005; 19:97-99.
27. De Lazzari E, Leon A, Arnaiz JA, et al. Risk of hepatotoxicity in virologically suppressed HIV patients switching to nevirapine according to gender and CD4 count. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 27-30 September 2006; San Francisco, California. Abstract H-1064.
28. Haas DW, Bartlett JA, Andersen JW, et al. Pharmacogenetics of nevirapine-associated hepatotoxicity: an Adult AIDS Clinical Trials Group collaboration. Clin Infect Dis 2006; 43:783-786.
29. McRae MP, Lowe CM, Tian X, et al. Ritonavir, saquinavir, and efavirenz, but not nevirapine, inhibit bile acid transport in human and rat hepatocytes. J Pharmacol Exp Ther 2006; 318:1068-1075.
30. Johnson M, Grinsztejn B, Rodriguez C, et al. Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures. AIDS 2005; 19:685-694.
31. Lankisch TO, Moebius U, Wehmeier M, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. Hepatology 2006; 44:1324-1332. This work identifies a UDP-glucuronosyltransferase haplotype which predisposes to hyperbilirubinemia in atazanavir treatment and may have an additional role as a pharmacogenomic risk factor.
32. Guillemette C, Millikan RC, Newman B, Housman DE. Genetic polymorphisms in uridine diphospho glucuronosyltransferase 1A1 and association with breast cancer among African Americans. Cancer Res 2000; 60:950-956.
33. Torti C, Lapadula G, Casari S, et al. Incidence and risk factors for liver enzyme elevation during highly active antiretroviral therapy in HIV-HCV co-infected patients: results from the Italian EPOKA-MASTER Cohort. BMC Infect Dis 2005; 5:58.
34. Sulkowski MS, Mehta SH, Chaisson RE, et al. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18:2277-2284.
35. Torti C, Lapadula G, Uccelli MC, et al. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients. Int J Antimicrob Agents 2007; 29:185-190.
36. Bäuerle J, Miquel R, Laguno M, et al. Hepatic steatosis with stavudine in HIV/hepatitis C virus co-infection. AIDS 2005; 19:1441-1442.
37. Walker UA, Bäuerle J, Laguno M, et al. Depletion of mitochondrial DNA in liver under antiretroviral therapy with didanosine, stavudine, or zalcitabine. Hepatology 2004; 39:311-317.
38. Zeremski M, Talal AH. Dideoxynucleoside analogues should be used cautiously in patients with hepatic steatosis. Clin Infect Dis 2006; 43:373-376.
39. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multidrug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 368:466-475. This study shows that serum transaminases are more frequently elevated with tipranavir than with comparator protease inhibitors.
40. Revisions to the safety labeling for enfuvirtide injection (Fuzeon). US Food and Drug Administration (FDA); 2006. http://www.fda.gov/medwatch/safety/ 2006/sep06.htm#Fuzeon. [Accessed 27 March 2007]
41. Nichols WG, Steel HM, Bonny TM, et al. Hepatotoxicity observed in clinical trials of aplaviroc (APL 873140). Tenth European AIDS Conference; 17-20 November 2005; Dublin.
42. Borroto-Esoda K, Vela JE, Myrick F, et al. In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Antivir Ther 2006; 11:377-384.
43. Moreno C, Gustot T, Nicaise C, et al. CCR5 deficiency exacerbates T-cell-mediated hepatitis in mice. Hepatology 2005; 42:854-862.
44. Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16:2165-2173.
45. Lebrecht D, Vargas Infante YA, Setzer B, et al. Uridine supplementation antagonizes zalcitabine-induced microvesicular steatohepatitis in mice. Hepatology 2007; 15:72-79. In this animal model a causal link between γ-polymerase inhibitors and steatohepatitis is established. It is demonstrated that the preventive dietary supplementation of bioavailable uridine attenuates all aspects of this hepatotoxicity.
46. Van Huyen JP, Landau A, Piketty C, et al. Toxic effects of nucleoside reverse transcriptase inhibitors on the liver: value of electron microscopy analysis for the diagnosis of mitochondrial cytopathy. Am J Clin Pathol 2003; 119:546-555.
47. Mokrzycki MH, Harris C, May H, et al. Lactic acidosis associated with stavudine administration: a report of five cases. Clin Infect Dis 2000; 30:198-200.
48. Chariot P, Bourokba N, Monnet I, Gherardi R. Hyperlactatemia and human immunodeficiency virus infection: lessons from the era of antiretroviral monotherapy. Antimicrob Agents Chemother 2002; 46:3683.
49. Brown TT, Li X, Cole SR, et al. Cumulative exposure to nucleoside analogue reverse transcriptase inhibitors is associated with insulin resistance markers in the Multicenter AIDS Cohort Study. AIDS 2005; 19:1375-1383.
50. Negredo E, Paredes R, Peraire J, et al. Alternation of antiretroviral drug regimens for HIV infection: efficacy, safety and tolerability at week 96 of the Swatch Study. Antivir Ther 2004; 9:889-893.
51. Duclos-Vallee JC, Vittecoq D, Teicher E, et al. Hepatitis C virus viral recurrence and liver mitochondrial damage after liver transplantation in HIV-HCV co-infected patients. J Hepatol 2005; 42:341-349.
52. Walker UA, Venhoff N, Koch E, et al. Uridine abrogates mitochondrial toxicity related to nucleoside analogue reverse transcriptase inhibitors in HepG2 cells. Antivir Ther 2003; 8:463-470.
53. Walker UA, Auclair M, Lebrecht D, et al. Uridine abrogates the adverse effects of antiretroviral pyrimidine analogues on adipose cell functions. Antivir Ther 2006; 11:25-34. In this in-vitro model of lipoatrophy, uridine was shown to dose-dependently prevent and treat zidovudine, zalcitabine and stavudine-mediated adipocyte toxicity.
54. Milazzo L, Piazza M, Sangaletti O, et al. [13C]Methionine breath test: a novel method to detect antiretroviral drug-related mitochondrial toxicity. J Antimicrob Chemother 2005; 55:84-89.
55. Milazzo L, Menzaghi B, Massetto B, et al. 13C-methionine breath test detects drug-related hepatic mitochondrial dysfunction in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41:252-254.
56. Venhoff N, Zilly M, Lebrecht D, et al. Uridine pharmacokinetics of Mitocnol, a sugar cane extract. AIDS 2005; 19:739-740.
57. Banasch M, Goetze O, Knyhala K, et al. Uridine supplementation enhances hepatic mitochondrial function in thymidine-analogue treated HIV-infected patients. AIDS 2006; 20:1554-1556. This article provides clinical evidence that the dietary administration of bioavailable uridine over a 3-day period normalizes hepatic mitochondrial function over several weeks.
58. Walker UA, Langmann P, Miehle N, et al. Beneficial effects of oral uridine in mitochondrial toxicity. AIDS 2004; 18:1085-1086.
59. Gattermann N, Dadak M, Hofhaus G, et al. Severe impairment of nucleotide synthesis through inhibition of mitochondrial respiration. Nucleosides Nucleotides Nucleic Acids 2004; 23:1275-1279.
60. Walker UA, Venhoff N. Uridine in the prevention and treatment of NRTI-related mitochondrial toxicity. Antivir Ther 2005; 10:M117-M123.